GlassScriptPhysician profile
Richard A Gordon
NPI 1972557585
$2,593.24
in general payments reported to CMS, 2019-2025
26 companies · $649 in 2025
The $649 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $40.21 · 2021: $38.61 · 2022: $172 · 2023: $659 · 2024: $901 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,208.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,101.12 | 2023-2025 | Azstarys |
| Novo Nordisk INC | $619.09 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Supernus Pharmaceuticals, INC. | $118.95 | 2021-2023 | Qelbree |
| Lilly USA, LLC | $116.38 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $81.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.46 | 2019-2024 | Jardiance |
| Dexcom, INC. | $48.72 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $48.65 | 2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $48.43 | 2022-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Kowa Pharmaceuticals America, INC. | $43.64 | 2025 | Zoryve |
| Collegium Pharmaceutical, INC. | $39.17 | 2025 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.64 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.51 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.44 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.63 | 2024 | Spravato |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.87 | 2025 | |
| Ironshore Pharmaceuticals INC. | $21.08 | 2022 | |
| Alk-Abello, INC | $20.65 | 2024 | Grastek, Ragwitek, Odactra |
| Astrazeneca Pharmaceuticals LP | $20.20 | 2024 | Airsupra |
| Exact Sciences Corporation | $15.99 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $14.93 | 2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $13.12 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.32 | 2019 | |
| Tris Pharma INC | $11.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.